Intercept Pharmaceuticals’ Phase III POISE trial meets primary endpoint
The pivotal Phase III POISE trial showed that OCA, at both a 10mg dose and a 5mg dose titrated to 10mg, met the trial’s primary endpoint of achieving
BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.
Pfizer Global Innovative Pharmaceuticals Business Medicines Development Group head and senior vice president Dr Steven J Romano noted as the number of hip and knee replacement surgeries performed
SmartFactory is a single-use cGMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, the